
    
      A study to compare the immunogenicity & safety of 2 formulations of GlaxoSmithKline (GSK)
      Biologicals' DTPa-HBV-IPV/Hib vaccine given in healthy infants at 3,4 & 5 months age. The
      immunogenicity & safety of DTPa-HBV-IPV vaccine will also be evaluated in a 3rd group of
      subjects Subjects in the group that will receive DTPa-HBV-IPV/Hib vaccine (current
      formulation) will be the control group for the group that will receive DTPa-HBV-IPV/Hib
      vaccine (new formulation)
    
  